Assessment of Treatment Response With Faslodex (500 mg) in Standard Clinical Practice Through a Retrospective Study.
Phase of Trial: Phase IV
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms EFFICACY
- 10 Jun 2017 Biomarkers information updated
- 25 Apr 2016 Status changed from recruiting to completed.
- 20 Aug 2013 Planned end date changed from 1 Aug 2012 to 1 Mar 2014 as reported by ClinicalTrials.gov.